JNJ · News · 20261104N

Impella Clinical Outcomes

JOHNSON & JOHNSON · 2026-11-04 · Importance 20 · Surprise 24

Johnson & Johnson released new real-world data for its Impella heart pump showing reduced mortality rates in high-risk coronary procedures. The reporting says the data supports the ongoing PROTECT IV trial and reinforces the company’s MedTech expansion in complex cardiology. PROTECT IV results are expected in 2027 and will help assess Impella’s long-term market adoption; no financial impact or adoption figures were reported.

Key facts

• Johnson & Johnson released new real-world data for its Impella heart pump showing reduced mortality rates in high-risk coronary procedures. source
• Results from the PROTECT IV trial are expected in 2027. source
• The Impella real-world data is described as supportive of the ongoing PROTECT IV trial. source